Octaplas Solution
Product Images NDC 68982-955

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Octaplas (NDC 68982-955). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Octapharma Usa Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image File (Img0001)

This seems to be a table that shows the results of a virus reduction factor test on production. The test was completed in one step (Step I). S/D (unknown acronym) treatment resulted in a virus reduction factor of greater than 6.18, or a value of >503 [log10], or an approximate value of 512. Global reduction factor was also greater than 6.18, with a value of 2503 [log10], or an approximate value of 2512.*

FDA Label Image

Image File (Img0002)

This is a description of Ocraplas Pooled Plasma (Human), which has been treated with Solvent/Detergent to make it suitable for intravenous use. It is only available on prescription and each 200 mL contain 9-14 g human plasma proteins, 0.88-1.48 g sodium citrate dihydrate, 0.06-0.24 g sodium dihycrogen phosphate diydrate and 0.80-1.20 g alycine. The product is free from preservatives and should be stored at -18°C or below, protected from light. The product should be used immediately after thawing, should not be refrozen or used if cloudy or has any signs of deposit. The manufacturer's license number is 1646.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.